Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

Stock Information for Sernova Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sernova Biotherapeutics Inc.

Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Sernova Appoints Jonathan Rigby as Interim Chair
Chair of Sernova Biotherapeutics Resigns
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.